Why Is AXSOME THERAPEUTICS (AXSM) Stock Moving Today?

AXSM stock is up 7.22% at $226.35 as of the latest trade, driven by recent developments in the company’s clinical pipeline and renewed analyst optimism. The stock opened at $212.00 and reached an intraday high of $229.62 before settling near the upper end of its range. The move follows a presentation at the 12th Annual Cantor Fitzgerald Global Healthcare Conference and a series of analyst upgrades reinforcing long-term expectations.

What Happened

Axsome Therapeutics has been in the spotlight after dosing the first patient in its SUMMIT Phase 3 trial of AXS-05 for smoking cessation. This marks a key milestone for the company’s pipeline and signals progress in its efforts to expand the drug’s therapeutic applications. The presentation at the Cantor Fitzgerald conference, featuring company executive Mark Jacobson, likely increased visibility among institutional investors and analysts. Additionally, HC Wainwright & Co. and Mizuho have reiterated or raised their price targets, with the former maintaining a $290 target and the latter raising its target to $316. These developments have contributed to the stock’s upward momentum.

What The Data Shows

AXSM is currently trading near its 52-week high of $260.19, having printed one fresh 52-week low and eight fresh 52-week highs on September 11. The stock opened below its 52-week high but has since climbed into the upper half of its range. Intraday volume of 0.3 million shares is in line with the 3-month average. On the fundamentals, the company remains unprofitable with a trailing 12-month net margin of -24.7% and an EPS of -3.76, but revenue has grown 56.9% in the same period. Despite this, the stock has a market cap of $11.0 billion and a beta of 0.71, indicating relatively low volatility compared to the broader market.

What To Watch

The stock is currently in a strong position as it approaches its 52-week high. Investors may want to monitor the SUMMIT trial’s progress and any further analyst commentary. No earnings date is listed, but coverage breadth and price action could evolve quickly given the recent developments.